Natural Ozempic Found: Stanford AI Uncovers BRP Peptide
- Jul 24
- 3 min read
Stanford Medicine researchers have identified a naturally occurring molecule that suppresses appetite and reduces body weight much like Ozempic — but appears to sidestep the nausea, constipation and muscle loss that plague the blockbuster drug. The discovery, made with the help of artificial intelligence and published in the journal Nature, is being hailed as one of the most promising leads yet in the search for a cleaner generation of weight-loss therapies.
The molecule is a peptide called BRP, short for BRINP2-related peptide. It is a tiny fragment just 12 amino acids long, produced naturally in the human body. In studies on mice and minipigs, BRP sharply reduced food intake and drove down body weight, echoing the effects of semaglutide, the active ingredient in Ozempic and Wegovy that has transformed obesity treatment over the past several years.
What sets the Stanford work apart is how the peptide was found. The team built an AI tool called Peptide Predictor to scan roughly 20,000 human proteins for small hidden fragments that might function like hormones. Out of thousands of candidates, BRP stood out. Rather than sifting through molecules one at a time in the lab — a process that can take years — the researchers let the algorithm surface the most promising leads in a fraction of the time.
BRP appears to work through a different but related biological pathway than Ozempic. While semaglutide mimics the GLP-1 hormone and acts on tissues throughout the body, BRP seems to act far more selectively in the hypothalamus, the brain region that governs appetite and metabolism. It also activates a separate group of neurons. That precision is what researchers hope will translate into fewer side effects.
In animal experiments the difference was striking. Obese mice given BRP ate significantly less almost immediately, and minipigs — whose metabolism more closely resembles that of humans — showed reduced appetite as well. Crucially, the animals did not display the gastrointestinal distress or the substantial loss of lean muscle mass that can accompany GLP-1 drugs, a problem that has worried doctors as these medications spread to tens of millions of patients.
The side-effect profile is more than a comfort issue. Nausea and vomiting drive many patients to abandon GLP-1 drugs within the first year, undermining their long-term benefit. Muscle loss is an even deeper concern, particularly for older adults, because preserving lean tissue is essential to strength, mobility and metabolic health. A therapy that trims fat while sparing muscle would represent a meaningful advance.
The scale of the opportunity is enormous. GLP-1 medications have become some of the best-selling drugs in history, reshaping the pharmaceutical industry and generating tens of billions of dollars in annual sales. Demand has frequently outstripped supply, and the drugs remain expensive and require weekly injections. Any molecule that could match their effectiveness with a better tolerability profile would command intense interest from patients, physicians and investors alike.
The researchers are moving quickly to test whether the promise holds in people. The study's senior author has co-founded a company to develop BRP-based treatments and plans to begin human clinical trials in the near future. As with all early-stage science, the leap from animals to humans is where many candidates fail, and experts caution that years of testing lie ahead before any product could reach the market.
There are also open questions the animal data cannot yet answer. Researchers do not fully understand how BRP is regulated in the body, how long its effects last, or what the ideal dose and delivery method would be. Whether it can be formulated as a convenient pill or would still require injection remains to be determined, and safety in humans over months and years is entirely unproven.
Still, the discovery highlights a broader shift in how new medicines are being found. By training artificial intelligence to comb through the body's own proteins for overlooked signaling molecules, scientists are uncovering biology that traditional methods might never have reached. BRP may be the first high-profile weight-loss lead to emerge from that approach, but researchers expect it will not be the last.
For the millions of people struggling with obesity and its related conditions, the message is one of cautious optimism. A naturally occurring molecule that works with the body's existing machinery — discovered by an algorithm and refined in the lab — could one day offer the benefits of today's weight-loss drugs with far fewer of their drawbacks. The next few years of clinical testing will determine whether that hope becomes reality.
Because this topic touches on personal health and body weight, anyone considering weight-loss treatment should consult a qualified medical professional rather than acting on early research alone.
Comments